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We used time-in-motion methods in a pharmacoeconomic sub-
study to a clinical trial to estimate differences in resource use and
costs between oral ibandronate (ibandronic acid) and iv zole-
dronic acid. METHODS: At the Week 8 study visit, administra-
tion, monitoring and the treatment of drug-related adverse
events were recorded in patients receiving oral ibandronate 
50mg/day (n = 4) or iv zoledronic acid 4mg every 3–4 weeks (n
= 5) at 2 centres in the UK. No patients were receiving iv
chemotherapy. Data was collected using a detailed nurse work-
sheet (diary), designed and pilot-tested in one center. Total use
of infusion supplies, medications, laboratory tests, procedures,
staff time and total time in the clinic were also recorded.
RESULTS: Administration of iv zoledronic acid required >1.5
hours more clinic time per visit and approximately 1 hour more
clinician and nurse time than oral ibandronate, due to infusion
time and patient monitoring. Over a 12-month period, the addi-
tional clinician and nurse time required for iv zoledronic acid
administration would be about 16 hours more than with oral
ibandronate, and there would be about 36 additional clinic
hours, including 28 hours for iv preparation and infusion alone.
Details on medical resource use for infusion-related supplies,
medications, laboratory tests will be presented. CONCLU-
SIONS: Oral ibandronate reduced the burden on health care pro-
fessionals, giving staff more time to treat patients, increasing
productivity. The absence of iv administration also frees patient
beds and improves capacity within health care systems. The
potential beneﬁts will be greatest for patients receiving 
oral anticancer therapies, or those who have completed iv
chemotherapy.
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COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER
DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)
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OBJECTIVES: To analyse the cost-effectiveness of CAD in breast
cancer diagnostic in comparison to normal procedure from the
perspective of statutory health insurance (SHI). METHODS: To
compare the effectiveness with and without CAD, total costs of
diagnostic measures were calculated by a Markov-model. Model
structure, transition possibilities, procedures within therapies
and complications were ascertained by a Delphi-panel. Subse-
quently, costs of therapy per patient with and without CAD were
calculated. Fur-thermore, costs of successive therapy of unde-
tected cancer without CAD were consid-ered. Based on litera-
ture, an increase of 19.5% in detecting breast cancer with CAD
was determined. Moreover the assumption was made, that with
CAD 19.5% of cancers could be detected at an earlier stage.
RESULTS: Based on perspective of the SHI, diagnostic and
therapy of 10,000 mammography patients from the Markov-
cohort caused total costs in amount of 2,298,048€ without CAD
(229.80€ per patient) and 2,352,635€ with CAD (235.26€ per
patient). By consideration of the effectiveness parameter (number
of detected breast cancers per 10,000 patients, 0.01912 without
CAD, 0.02285 with CAD), the effectiveness-adjusted costs
amounted to: without CAD 12,019€, with CAD 10,296€. Thus,
the implementation of CAD proves to be more cost-effective due
to a higher sensitivity of the diagnostic procedure.Subsequently,
two sensitivity-analyses were conducted to test robustness of this
model for cost effectiveness and for costs per patient relative to
the price for CAD. CONCLUSIONS: Diagnosis costs per patient
are higher with CAD compared to normal procedure. However,
more breast cancers can be detected and treated at an earlier
stage. Therapeutic costs per patient are lower; therefore imple-
mentation of CAD is more cost-effective. As far as Germany is
concerned, 2.691 additional breast cancers can be detected every
year if CAD would be included in breast cancer diagnosis.
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OBJECTIVES: Cost-effectiveness (C/E) studies of oral vs iv reg-
imens are important, with the availability of oral regimens
having “iv efﬁcacy”, and some iv regimens being available as
generics. C/E of oral ibandronate (ibandronic acid) versus iv
zoledronic acid or iv generic pamidronate was assessed in breast
cancer patients with metastatic bone disease undergoing iv
chemotherapy. METHODS: The model assumed a UK NHS per-
spective, 14.3 months expected average survival, concurrent iv
chemotherapy lasting 4 months, and speciﬁed probabilities for
bisphosphonate discontinuation. Primary outcomes were direct
Health Care costs and QALYs. Resource use for iv bisphospho-
nates was obtained from a published micro-costing study (vali-
dated by UK clinician); the cost of managing skeletal-related
events (SREs) came from published literature. Other costs were
calculated using a unit cost database. Monthly drug costs were
£195 for oral ibandronate and iv zoledronic acid, and £165 for
iv generic pamidronate. Renal AEs with monitoring and treat-
ment costs were assumed for zoledonic acid. Efﬁcacy was
assessed as the relative risk reduction (RR) of SREs (assuming
SRE duration of 1 month). Utilities were applied to time
with/without SRE, to adjust survival for patient QOL.
RESULTS: Projected total cost (including drug) was £386
less/patient for oral ibandronate than for zoledronic acid, and
£1171 less/patient than for generic pamidronate. Due to SRE RR
and pain relief, oral ibandronate gained 0.02 QALYs, making it
the economically dominant option versus zoledronic acid or
generic pamidronate. For completeness, C/E results for iv iban-
dronate will also be presented, demonstrating C/E. CONCLU-
SIONS: Oral ibandronate was highly cost-effective compared
with either iv zoledronic acid or generic pamidronate. The 
efﬁcacy of oral ibandronate in preventing SREs and sustaining
relief from metastatic bone pain is likely to lead to QALY gains,
with cost savings due to reduced Health Care staff time for
treatment of SREs, bisphosphonate administration, and patient
monitoring.
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OBJECTIVES: To compare the medical and economical impact
of four strategies in the prevention of colorectal cancer (CRC)
in France: 1) no treatment no surveillance; 2) chemoprevention
with 325mg daily aspirin; 3) colonoscopic surveillance with a 3,
5 or 10-year periodicity according to recent guidelines; and 4) a
combination of the two latter ones. METHODS: A Markov deci-
sion model was built, following a ﬁctive 50-year-old cohort
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during 30 years, in order to realize a cost-effectiveness analysis.
The probabilities to be entered in the model were deﬁned after
an important review of literature. Efﬁcacy was assessed by 
incidence of CRC and life expectancy in the model. The dis-
counted costs considered were related to cancer (diagnostic,
treatment), chemoprevention (treatment, side effects) and screen-
ing (colonoscopy with or without polypectomy, complications),
under a society-based perspective restricted to the health sector.
RESULTS: When a 80% reduction in CRC through screening
and a 30% reduction of adenomas through chemoprevention
were assumed, the most effective strategies were also the cheap-
est. While 5090 CRC for 100,000 persons are expected in a pop-
ulation without intervention, 1380 CRC could be avoided with
a chemoprevention, 3230 with a colonoscopic program of sur-
veillance and 3800 when associating colonoscopy and aspirin.
The life expectancy in the model is 16.22 years with a cost-
effectiveness ratio (CER) of 696€ for strategy (1), and 16.63
years with a CER of 371€ for strategy (4). With a percentage of
amelioration through screening reduced to 50%, the results
remains in favour of the strategies (2) and (4), while strategy (3)
is no longer cost-effective. CONCLUSION: Results emphasize
the importance of a regular surveillance. The cost of cancer is
high enough to condemn the absence of prevention.
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CELL LUNG CANCER TREATMENT WITH CISPLATIN-
ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-
GEMCYTABINE
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OBJECTIVES: To evaluate the cost-effectiveness of cisplatin-
etoposide (PE), cisplatin—winorelbine (PN) and cisplatin-
gemcytabine (PG) combinations recommended in NSCLC 
treatment in Poland. METHODS: Medical care utilization data
and survival data were collected retrospectively in medical
centers in Poland (Warsaw, Poznan, Cracow and Wroclaw);
among patients with advanced non-small cell lung cancer (stage
IIIb and IV), who were treated with one of the analyzed regi-
mens and had not had surgical intervention. The payers’ per-
spective, which in Poland was The Regional Insurance Agenda,
were chosen for the calculation of cost. Only direct medical care
cost were assessed. All medical care consumption (including cost
of diagnostic tests, hospitalization, ambulatory care and med-
ications) were estimated from the patients’ chart and the infor-
mation of costs were derived from the Financial Departament in
each hospital. All cost were in polish zloty (in 2001: 1$ = 4.14
zloty. RESULTS: The highest average cost of one patients
chemotherapy was for the PG regimen (26,016 polish zloty),
almost two times higher that for PN—11,642zl and PE—10,350
zl. The cost-effectiveness ratio was 30,850zl, 37,792zl, and
56,983zl per life year gained for PN, PE, and PG, respectively.
Sensitivity analysis conﬁrmed that the factors that affect the cost
of treatment had not had an inﬂuence for the ﬁnal results.
Whereas the value of cost-effectiveness ratios were sensitive to
the factors that affect the effectiveness of chemotherapy. CON-
CLUSIONS: Our analysis showed that the combination of cis-
platin and winorelbine is more cost-effective in the treatment of
advanced NSCLC compared to cisplatin—etoposide and cis-
platin—gemcytabine regimens.
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OBJECTIVES: ALCEA (Advanced Lung Cancer Economic
Assessment)—an observational cost-of-illness study—was aimed
to investigate the economic proﬁle of the advanced Non-Small
Cell Lung Cancer (NSCLC) in Italy. METHODS: Information
on health care resource utilization was collected on 189 patients
affected by advanced NSCLC and treated with ﬁrst line
chemotherapy (1stL), second line chemotherapy (2ndL) or Sup-
portive Therapy (ST), for a 6-month period or until death.
Resources were costed according to current Italian tariffs.
Average management cost per patient and monthly average per
patients costs (MAPC) were calculated. RESULTS: Overall 
125pts received 1stL, 62 2ndL and 53 ST. Average cost per
patient was 8.265€, 5.148€ and 3.389€ in 1stL, 2ndL and ST,
respectively. Hospitalization was the main constituent of cost in
all lines accounting for 62% in 1st L, 68% in 2nd line and 77%
in ST. Costs of drugs prescribed at home ranked second in all
lines (12%, 11% and 10%, respectively). Cost of radiotherapy
was negligible in 2ndL while ranked third in 1stL and S (10%
and 9% of mean cost, respectively). Monthly cost of chemother-
apy was higher in 2ndL than in 1stL as more expensive agents
are frequently used. Due to their general conditions, patients in
2ndL generate higher adverse event costs (MAPC 269€ vs. 218€
in 1stL) and ST patients determined higher hospitalisation costs
(MAPC 2.298€ vs. 1870€ in 2ndL and 1.156€ in 1stL). CON-
CLUSIONS: NSCLC management imposes a remarkable burden
on the Health Care system in the advanced disease stages.
Although costs reduce from 1stL to 2ndL and to SC, even the
latter has a signiﬁcant economic impact. Strategies that can
reduce hospitalization (including oral drugs or home assistance
burden) could help lowering the cost of advanced NSCLC.
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OBJECTIVES: Gemcitabine (Gemzar) belongs to new third-
generation chemotherapeutic agents that are now commonly
used in combination with cisplatin or carboplatin in advanced
non-small cell lung cancer (NSCLC). We compared the direct
health care costs of a gemcitabine/cisplatin regimen (Gem/Cis)
with paclitaxel/carboplatin (Pac/Car) and vinorelbine/cisplatin
(Vin/Cis) regimens in the treatment of NSCLC in France.
METHODS: The economic analysis was performed based on
chemotherapy and medical resource utilisation by 612 patients
in the randomised, controlled trial published by Scagliotti et al.
(2002), which found no difference in efﬁcacy between the three
regimens. Trial data were combined with unit cost data from
French ofﬁcial DRG charges for chemotherapy medication (reim-
bursed over the DRGs), chemotherapy administration, hospital-
